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3 LOI1~' ICl"ll1 EHectiv ness 
;\bSlliICI 
Benzodiazepines. particularly lllpl;17Id;tlll. IlilV\:, IH.':CIl sl (WI to b 
effective in the aCllte. tle:.ltl1ll'lll '11' [1i11l1C disUld\'I, Difficult 
withdl awnl and high relapse tall'S ;i1'lcl \LJCLc"JlIl disc ntinuation 
cOlltinue to e problem') wi!/) Illis rl.l'is \)1' 111'1 Il JtiOll, Recent studies 
in, titLlting cognitive-bdw\ i(lIill tlH,r;1I Y ilS ;\ Ilca[IlICnl supplement 
to alp '\zolam lapel', he ve sltU\', II I" 11111Slll!! rL' tl,1 aLit 1(1 ne year 
j Ih1\\-up. Till: present study II! l',ll:.\Il'l1 \\Ill'l \ll [11;11 Lombincd 
treatl1ll.:nt te LIlt III [0112-tl.'llll 111111\ \ ,'IJIlII !"llllI1IS w\.'re 
a Ipi a~' 1lim-oIl! y ~ I'd II P ur till' :. II il 
I \' \. -I 
the ,tud)', During tile :2·I-·I~-II1\'lllh ! I!. II ';11111"111 C\.tlll:llion, 
ncar v
. 
70% of those reCei\'111!2 
~ 
l'ultll'llll'(! lrcatll1cllt had rel1lail ed off 
drug or other supportive p:ltlic dislJldcl tllcrap_ ulillpaled to the 
307c: 101 the alplaLolalll-c nI' l..:,llllljl 1r )II) Se(lIL' ('11 scll"-lcpurt and 
clinician-rated measures, tile c I1lIJilll.'.d (l'caLJncl1t appe< led to haY 
been effective in producing a !li~l) cild-slalc ClIllclioning as well as in 
facilitating alprazolam discOl1lirllLlliull. 
4 Lon~-lcrl11 EITeclivcnes 
The CUIlII kuoll r I lis I'ill.ll'l.l '1111d IIO! Ila\l' Ollllllt:J withoLlt 
the inv:.tlual k .1 i,lilllCe, gllid:llli.l'. "11 i 1111'1I1 IIt11l1 111' 1ll11lillee 
Inemhers and LIII,\: friends, i\kl1liollillC! \\llil ILlllle hell' ,I l'S not do 
juslice to the till' YOll sacrifiu.:d t(1 "'l' tl1~11 111\ 1l','ll':lJlll :\ 
, II' ;11 r )1'. Iextcnd 
II 'L; 1 II' 
III ll~ flll 111'111' I: I t I (I ill. d 
'.e,hlc,sL'. til ,dLtl l () h.: :t I JI II; I It:l \'(' Il l-d no\\ 
III' C 1111.: ".r 'II I " \, , , I' II III I, 
.11 
J () III \ pL I \' ('111 d IilL' l' ' •• 1'.11 !I .11\ Idudl 
pallilular: Lalild l h,lpll1<1n ;111(\ 11';11111 \\ I,' 1\.'1111·11. '111011,~h Cllil 
n;s~arcl Oppulllillilic, livcr"ctl !lli;. I.l.{ .\C;II', I i1L1ld (\1\ I IT mai ned ~ 
spheres. Her moral support dllt! ;111 .llkllli\ c Cill' :l.re cl1l!L-;lring 
qu::l1ities that J malic. u e or 111d11\' lillll'S \\·!ICll lIn olle '1,\(' would 
understand. 
And LCillll1. \\lll)S~ ahilil 
' 
\\'1 1'1l hill' 111,111' uf III \ I ul-even­
remotely-funny "toties ell rOllte In 1\:1\1 i;\. 11Cljlcd l1le (0 see the 
proverbial light at the end or tile I)s th rl()1 (ul1l1el by rel11inding me 
thal everylJ inn \\111, Illdecd, gel "Olll. I· HJugh lilt.: lil1ll':-' \\Clt.: busy, 
5 l~ong-lcI"l11 Etlecliveness 
the fellowship was Il1cmoral\lc, all i all clldliring l'riencJship, 1 hope 
will be born of ur 1111tu,l! cxpcriclllcS Ihis yC;11 
As for Dr. Bruce, Tim Bruce, wllOse illSislcl1ce that I take lip the 
way of the King if I am c er gOlll~ 10 Ill:lke it ill Memphis, lowe far 
more than some trivia b ok or mil ul lube si.xk". For the cauiltle. S 
hours spent revising per,ollal sl;IIClllCllls. propoq! draft:', and I'inal 
papers, I pause, face the llCrtl,c;ISI, dlld IIL\nk Ihe Great RastQr that 
this mall, who d es \vl1,ltcvn hI.' docs lJel\Vccll Ille hours "r J 1 a.m. 
and 2 p.m., has bestowed lIPOll ll1e Ille .l'<ll: \)1' wisdolll th:lt call only 
come from seeing DallY i\lallilo\V I :I!:l·d. hd\'ill~ a lllilJiunairc. orolher, 
and asking rhetorically. "Js 11l:ll ~lolht'l' Crcl'll'.I' 
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LOllg-term Effecti\ enL. s of Combi ned Alprazolam 
(lnd Cogni ti ve-Beha y ionl Thel apies in Panic Disorder 
Panic disorder with agoraphobia (PDA), which has a prevalence 
f one to two p rent in the general pupulation. typically begins 111 a 
atient's mid-twenties anJ oeeuls twice as frequently in women as in 
men (24). Like all anxiely di,on.ler:, it has the trademark symptoms 
of anxiety anJ avoidan e. llowe\' r, I DA can be distinguished from 
other anxiety disorJer., e. pellally phohia" by the characteri. tic 
". POl1tJIlLUll." panic alld\.'k .. \\ 1111.:11 alc not reli.lll!y and exclusivel\' 
eliciled hy some specific ohjecl or 'llllation. Cunsequently, panic 
patients ran experience the uttacks wilh no forewarning and no 
preJI,'live .tilllulus (l..jj, DUlillg tile dllacks Jl~ltit:nt may eXperll'llCe 
an. (If the I\)llowillg s. I11pIOI1l~: shortlless 01 hI ':JIlL dizzille~ , 
tachycardIa, trembling or shaking, ,weating, Llloh.ing, nausea, hoI 
±lashes or chills, feeling of numbness or tingling, depersonalization/ 
derealization, a fear f dying, or a fear of g II1g razy without the 
ability to control on's actions. To meet th diagnostic criteria f01 
PDA, a patient must experience at least four of these symptoms 
during a panic attack and begin avoiding situations for fe r of their 
recurrence (2). 
III agar phobia, palit;nt lend to modify their activitie In order 
to avoid situations in which eseaI c might be difficult or impossible, 
help may not be available, or embarrassment might result if another 
panic attack occulfcd. This modifi alion, term d "[ear of fear", IS 
oft n targeted in the curse of treatment (15). Certainly panic attacks 
7 Long-tel m Effecti venes. 
thaI Ie ull llum u'd and uncucd : limuli <lIHJ tile anticipatory 
an. I'tv III In olle <Junck 10 the ne.\l l'JIl greatly ldfet.t the l1orm~1 
funclloning oj an individual. 
fhe tv.o primary treatment Ill\ldaillie" l)! PD1\ are 
phallll;\(;()I-'giL' and llunpharmacoll)glC. BCIlZodi;ul'IIIlCS, the onl .. 
ll1ectl ati 11 (01 PDA approved by the r llJd and 1)1 L1~ Admini 11 at \)11. 
ha\ ~t'\t'lal ,HJvantao('s: their al1[lpank plOpl'( ic.., aIL e\ldeIlI 
aIm .l il11l1h:di: tel) \~ ,: tlH:il elll .tllt ~ 1<- I :lllllalned (l\el "'t' 
Il L III rt , nd 11lrl~-1c1111 ha\(' 11 t
" lem ,h(,I~(, llICl'1 \ Jl allY I)J ", II l t, led J 1:, al~ \ it 1.1 
Itt II I !l,d I ).\ Gillin . 1l)I)O) • II ;lll I hl' III dl,IZCpillt: a Ilk 
~ltl I III III Lhnll( 1'1 Illl II ( I • :1 Ill,G1I1 Il u~e, 
I ;. r Ill: r till) It 
oj '\ 1i l rl. <l.llllan J 11\ Illd :, lll1d • II <.l1J t: I I IlJ ' ,11\)\\ co III;. I II c 
benZIKliazcpines enhance the wl\k~preao inhibilll y acti ity r 
gUllll1lu-amiu(Jbutyric aliJ (G!\.BA) In lhe brain 1101cover, thl 
jU:\l< Illsitiln of the GAB!\. anJ 'l.:fll"Jiazcpinl' Ill'C'!"IPrs 011 thl <,al11l' 
r eeplor c mplex and their nece .. ary joint stimulation is resp nsible 
for the influx of extracellular frce l'hloride ion, and the sub equcnt 
inhibited firing of those neUlon[., (14). A high \..\JIllGIItfation uf 
benzoJiazepine-GA13A receptOl Lvi IPle.XC~ is foulld in the locus 
e ru)eus, the primary noradrenergic nucleus, hyperactivity of which 
has been considered to be centrally involved in the etiology of PDA 
(for leview, sec G 1'11lun el aI, 1989). By rcduling the nOlepine hrill\.. 
acth it_, in the overstimulated projections of the l(Jeu eel' leu with 
8 Long-lerm Effectiveness 
bcnzodiazepinc . an overall allel1l1alil)n of Yl11ptOl1l~ Ilamely a 
uppression of tile sponlaneous paniL allacks, can be <ll!licved (J 7). 
lpi azolarn, a high potene b nzodiazepine, has been shown in 
lalg trial.' 10 be a particularly clTiLacious trentmcnl IIlO lality for 
PDA (28, 3). De, pite the clear benefit of alprazolam, it also has 
drawback- Alprilzolam induces lrue phy,iological depl'r1lkncc and 
shows a dl. tinct withdrawal syndrome when discontinlled (23). 
\'ithJli.l\\.d .~ll1ptOll1S call inclUUt: a~ilati n forgelltlllc,s. tf mor, 
1IlS011111li.l nall .\\eaLJI1~ anJ [.tel l;lIUlti. TheIl.' I.. blcn \)nly 
riue ill Will '; here bt:l1zodialcjlllll.: di.lontinllalil/l I.! elicited 
raran ii.!. Sl'\t'l" tlcprc.si n. delerium, or glalHJ mal L'11Ure (14), In 
additioll 11 tilt: l'pl'n knc' anJ withdrawal C 1ll1pli ·.lti, I,. 
aJ~)Jaz\,hr tllr.!]! !las bl'l:11 cllala Ililled Iv hiLlI r .1 e lale' 
( 10). 
Givcn its widespread use in lh~ clinical trealmCIll of anxiety 
di ordels. melltal health professional ha e bcen pI' posing se eral . 
strategie. Lt :lllH~liorate discontinu:ltil)11 symptom. Ihat complicate 
alprazolam taper. One such method of facilitating withdrawal 
involves the temporary addiction to other medications such as 
arbamazepine, imipramine, Of bUSPll'L)I!e during taper ~26). A study 
by Ri -s, Roy-Byrue, Ward, Neppe, & Cullison (1989) . howed that 
patients given carbamazepine before rapid discontinuation of 
benzodiaz pin tolerated the taper well with no one reporting 
significant withdrawal symptoms r sidt: effects. AnotlH.:r suggested 
treatment strategy consists of modi fying lap r by changing patients 
9 Long-term Effectiveness 
from an intcrmcdiatt?,-aLllng benzoulaz 'pine (alprazolam) to a 
longer-acting at:cnl (clon<lzepam) berol the initiation of 
discontinuation (14, IL While these . tudics show that medication 
trllt gie are helprul when taper is rapid, a sl w flexible taper IS 
,ufficient to assist discontinuation; howev~r, rclap. afte' 
di. c ntinuation remains a problem (30. 19). 
The majOl nllll-phannaclliogical appr lJeli to PDA i 11\ olvt:s 
cognitive-bel avioflll thLrapy (eBT). A plllllar Larget or CST is \0 
lulucc the 'ata'tlvphic mi, inlerplelatilll uf panIc '. mill 111:- such 
a: cardiac Jlrh dII1lI:J. I'realhlessnc.. Jnd lightheadednc.- . \\hieh 
way be percch cd a heart aUaek prel'lIl SOl'S instead (thL somatil 
,L 11 ~lliun. II II'. I I)\, I <II. iety le~pull. c (9). 
COglllli l:-llha\J(II;.1 thel<lp) la. 1t:t:1\ hU\l1 tll Lin: high 
;.Illlle trcalllll'lll ~1Il' t: s tUles with 10 lliapst: lalL'''. !'tH c.\nlllpk. 
CIJske, Brown ami Barlow (1991) assessed 4J panic disorder 
patients with millJ or no agoraphobic avoidance who had panicipaled 
in either progressive muscle relaxation, interoceptive exposure 
therapy and cognitive restructuring, or a combination f both 
conditions, Of the patients receiving cognitive restructuring, 8Ill 
remained panic-free at two-year follow-up. Similarly, a study 
examining the treatment of agoraphobia at two y aI's demon. trated 
that agoraphobics undergoing eBT maintained an imp!' ved end-state 
functioning ov I' 24 months when a spouse was involved with 
therapy (6), 
Long-term Effectiveness 10 
eBl' formulations suggest that the withdrawal symptoms 
experienced by patients during bcnzodiazepine taper may be related 
to the difficulty in discontinuing their medications, in light of PD 
patients' heightened anxiety and concern about bodily sensations 
(e.g. Otto et aI., 1992). Several t.rials int.egrating CBT methods into 
alprazolam taper have produced promising results. For example, Otto 
et a1. (1993) assessed the efficacy of a cognitive-behavioral program 
for 33 pat.ient. with PDA wh were disc ntinuing treatment with 
high potency benzodiaz pines. Panic patients randomly as. igned t.o 
drug conditi n or drug condition with t.en w cks of concurrently 
t.aught CST were tapered orf of al prazolam or clonazepam (mean 
subtherap utic do e=1.3 mg/day anu 1.5 mg/day resp cli ely). 
u<.:cessful discontinuation of bClllodiazepinc treatment wa. 
significantly lower for those rec iving slow taper alone (2 -%) than 
for those who underwent cognitive-behavioral restructuring during 
taper (76%); 770h of the latter r mained fr e of benzodiazepines at 
three-month follow-up. In a similar follow-up study, Bruce et a1. 
(1994) reported that panic disorder patients who received combined 
alprazolam/CBT experienced fewer symptoms at three months and 
were overall better responders to alprazolam discontinuation. 
Spiegel, Bruce, Gregg, & Nuzzarello (1994) also assessed 
patients (N=21) who were made panic-free with alprazolam (mean 
dose=2.2 mg/day) and then assigned to either slow, flexible drug 
taper or drug taper with 12 weeks of CBT. At the completion of the 
study, there were no significant differences between the groups 
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concerlllng the rate of alprazolam discontinuation; however, at six 
month f IIow-up, 50O/C of the alpr zolam-only group (1 =10) and none 
of the combined alprazolam/CBT group ( =10) relapsed and had to 
reinstate pharmacotherapy. This result suggests that the drug taper 
protocol wa sufficient t incr ase the discontinuation rate but the 
CST prevented relapse. Another long-term fullow-up at one year 
showed 76% of the patients were medication-free and 85% were 
pam -free after a CBT modd was employed t1uring drug taper (18). 
Although these r suits suggest that en 1 can help patient 
ue 'essfully discontinue alprazolam and mailltain gains through SIX 
month to one-year evaluation" treatment combinin p ychotherapy 
and benzodia7cpines ilre not always beneficial As wa. shown by 
Mark. et al. (1 (93) III I1C large trial, impkmenting anxiety 
management techniques and ill vi 0 expo ure therapy as treatme11l 
supplements did not produce encour ging results. In that study 
there were no significant differences in relap e rates between the 
CBT-only group (56%) and those receiving CB after drug 
discontinuation (52%). C nsequently, it remains controversial if 
combined therapy will be as viable a treatment modality as CBT-only 
over long-term assessm nts. 
To our knowledge, no studies have il ve tigated the eHects of 
combined CBT and alpraz lam at long-term follow-up. The purpose of 
the present study was to evaluate the clinical functioning of 
combined alprazolam and CBT at two- to our-year assessment and to 
see if efficacy is maintained. We hypothesized that individual 
Long-term Effectiveness 12 
fec iviIlg CBT during taper woulJ be more successful in remainIng 
drug abstinent compared to patients who taper off alpr zoInm 
without concurrently taught cognitive-behavioral therapy. We also 
predict d that members of the combined group would maintain their 
therapeutic gain through long-term follow-up. 
Method 
Participants 
Panicipanl. were recruited from tile patient pnJlulation at the 
Uni versity r Illinois Coli ge or Medicine at PeoJ la who met the D t-.1­
III-R diagnostic criteria for panic uison.ler with agolilphobia of at 
lea. t SIX monlh. I duratlOll. Assessments were made with (he Anxiel\ 
Di .. I'd T' Illll'( lew chedule-Rc 'i t:d (ADI -R) (I~) an:l the 
Structured Clinical Interview f r D'M-lJI-R-PeJsonality Di orders 
(SC1D-1I, Ver. ion 1.0) (31). Patients were excluded from the study if 
they met DSM-Ill-R criteria for all organic mental syndrome, major 
mood disOJ del'. or obses~ive-compuL ivc d i, OJ del; had been tr ated 
previously with cognitive-behavioral therapy for panic disorder~ 
were presently in psychoth rapy, or were taking other centrally­
acting medications besides alprazolam. Similarly, if patients 
presented with mental illness, pregnancy, lactation, or a hi. to y of 
psychosis or drug d pendency within the past year, they were not 
included. To be considered for the study, patients had to have 
alprazolam as their only centrally-acting I edication in daily dosages 
between 1 and 10 mg. They also had to be free of spontaneous panic 
13 Long-term Eff ctiveness 
attacks for at least four weeks. For those individuals who met all 
criteria except these, a washout period follow d by alprazolam 
stabilization was institut d before their enrollment into the program. 
Twenty-four participant. were included, four men and 20 
women (mean age=38 years, average duration of PDA=12 years). At 
screening, of the 15 who were on an iolytics 12 were takin c 
benzodiazepines, and one patient each was taking buspilone. 
propranolol, and ue, ipramine. 
All participants pre. nteu with symptoms at creenll1g despite 
bei ng on pharmacotherapy. Patients su ffercd from a weekly average 
of 1.6 pan ic allacks and 4.6 limited ymptom attacks before 
lllprazoJam stabIllzalioll. Ovel 70% 01 the group LllmpJained of 
nocturnal ranic episoJt::s. FOJlOWII1£ DS,l-lll-R critci in. 1~)II( 01 the 
patients were rated as having mild panic, whereas 52% and 29% of 
the patients met the guidelines for moderate and severe paniC, 
respectively. Agoraphobic avoidanc wa rated as mild for eight, 
moderate for 12, and e ere for une l)f the pntients. Farly-eight 
percent of the roup had one additional anxiety disorder, while nIne 
percent met criteria for two or three. Specifically, the comorbid 
diagnoses included general anxiety disorder (33~), simple phobia 
(29%), and social phobia (9%). 
Each person wa stabilized on alprazolam before enrollment 
(mean duration=6.3 weeks, including four weeks following the final 
stabilized dosage). The ill an alprazolam dose was 2.2 mg/day. 
Long-term Effectiveness 14 
Treatments 
After alpraz lam stabilization and enrollment, participants 
were ran omly assigned to eilh r an alprazolam and tap r with 
supportive medical management (, =10), r the identical treatment 
with twelve w eks of concurrently taught cognitive-behavioral 
therapy ( ':=14). So as to minimiz~ patients' bias again. t the drug only 
condition, all participants were lold that the study was can panng 
two method of all razolam administration and di. continuation. Each 
person consented to random assignment and the institutional reVIew 
board approved of the handling of human panicip nts. 
T 'catment integl ity was monitored through random 
assessment of 300/, I the c gllltJ\e-behavioral and. upportive 
thclap) auLliotaping.. TI~atJnel1L adherence scales by Barlow and 
Craske were lIsed to heck the cognitive-behavioral sessions. To 
ensure patient compliance with the pharmacotherapeutic protocol, 
weekly pill counts, patient diaries of alprazolam use, and s rum 
benzodiazepine levels at two, six, and 15 weeks post-taper were 
employed. 
Pharmacotherapy. Alprazolam maintenance and taper consisted 
of two phases which were identical for both groups of patients. The 
stable-dose maintenance phase (m an duration=ll.O weeks) 
reflected that time during which the patient was maintained on the 
pre-enrollment dose; the taper phase (mean duration for those who 
completed taper=6.5 we ,ks) included a decrease in alprazolam 
dosages in open label fashion every seven days until either 
15 L,wg-lCll11 Err eti yen ,S 
11111111;1111)11 
• all y III JIll t' r cpcnlillg (1) the lllill,1 111 It'lance (jost'. 
!.I(lcipant. dail) alprazubll1 l/ltake \'a tapl'lld luwn t 2 mg. thell 
II i, I. r) . (J ,75. () ..-, n.J 7:, ( 2-, II 1:2 ~, 'I I I 1111; II ( I Ill); • 
III I ('lli\t, 1l1cdlcal Illdlla~CI1l'lt It wa pI uvidt:u 
Ie. t;1 b!l'-d ,l' aJld 
II \ i it lOll i led (I 
II al 
. inCll 
I I. III IIIJ t I 1.III,\. 
11ltlnuaL ul'\L'lllpeJ bv B<l11 \ dllJ CIa, kl' \ Il)~l)), TfL'dllllCllt 
IIlLJUUt:J eUUl;lliOI1 abOll 1.lI1IL disorJer, Jial'hrapnalll hllatlIini:-
Illll~, l\ II' L fl, II J , II J i III I l 'I I, L XI \ Il' , ') hl: 
Litter \Va. iniltalCd ,l thl hcginning 1f dru o taper whcrea<; the 
t Illler thre\.: a~peclS or thL1'ap~ \-ver 11ltroJuclu during the stnble-
Lgllili ,c bchavlulUl scssi II, :.Jlte) whiLh Illlle. IhL pall 'Ill had 110 
contact with the intervening lherapists. 
Measures 
/\IPltlLU1:J1I dl~<;OII 1,1 allOll, The Jlllll1ill: ,uICUJI1L: measure d 
Ih' nUIII be I \ d 1[1<.1 j \ iJ 1I aI . III completed all <;\l'p of lancr in the 
Long-term Efkcti eness 16 
time allottcu I,:! the treatment proto 01 and who diu I I[ r~lapse back 
on 10 pltaJlllilll hcrLlpy or ClllOll In alternLlti' PO.'\ tl almenl 
throughouL LIt~ IW 1- to fOllr-Yi:.'H folIO\\'-up, 
Clinician-faLed and self-report asse. smenl "erl' done at 
baseline, tlllCc:-Il111l1lh post-taper, and lWo- to fOIII-~ I.: II po. t-tapef 
fo])o\\'-liP L lilt the heellun IJanie iJnd Al1tlCipIII()l~ ; ILiety 'cale, 
the U(CUIICII 1.:' Ilf panll aHa 'k. OJ Iinlltcd SYl1lpl!llll HII. ck during 
tht.: pI II IIIl t t \\eek, llnd lhl. ill L:11. il\' (l 111111" ' f\' all'detv 
LJ 1 '( de~ ~ hlated (2' I'alielll ltilf jill. I \ a 
d l' cd . I1xiet y Di ol'lkr Ir ILf \ il.'\\ • 1I1l..' !LA I t:af U.), and 
IIICI le\\.: IlljJlwbil: 'l\lliJ,tnll l.htll 31 Ile \'..1 I' d by US1J1h 
tilL: lul1illl II cJllorv tIl( AglJlllpl1l hIl.I lSI. l Ilgllltl\' 1lLlles oj 
II .. l: I U-ill lite Il I II 11\ il\ II II .- liltr 
J ~i)rapllul I (, ~Illliun. (2uesLiol111,IIJ' 17) (l1d the Lilli ollal (. :'lIllI',)) 
Que, Ii nnaire ([-{arce, raske, and Ballow; presented at the ] 989 
annual meetin~ of the Association fOI Advancement ul Behavioral 
Tile J<I PY) nt:j Ie. s' \) n wa~ III ('; aSUI ~ d \. i III the B~ l k 0 t: J •.... Ion 
Inventory (4) (s ,e appendices A-G). 
Re LIlts 
Participants 
One participant In the combined alprazolam and CST group did 
n t compktl: lup\....! UU Lo LIl UiSLU\ LI 'j that he hau bt:en started un 
a centrally-actIng Jrug regimen other than alpraz lam lor a m dical 
17 Long-term Effecti veness 
condition not relalC'1 \l anxIety Three palJl.'nts (tw 111 the \.li Ig-Oltly 
(1roup and olle in \)" , III billed gWUp) haiku 10 complele all lq ~ or 
taper. Among the 1L"111~lillJl1g 20 incli\ jUlia\;", ] 6 JWllHlgeu to L'uJ1Iplete 
t'lpCI wilh the st:lllll;.rrd ,\eekly dose IcuucliollS. three aCl'{)Illpli. hed 
taper with one exlla \'.n:k requireu, a ld nllC' Ileeded an additillnal 
lint" week~. 
r-..\ e jI I II. 
.IIlLlI)SI \~Cll i' IlIllCd 111\ \;1 ah~1 
L. • I a I .\lIClt: I 1\ l I) trc;llllll'1 1 ~I I ,1Ih 
rcpl.:ll\.: I me, Sllre III variallLl' t .• ()\! . I III ;1. l II 
1,\.1111111 IY bLl 'I.ll ;1' l 1I11'( Ill'lllll 
n'll t:l,!­
I all 'Ill \\111 ill' II II. I'J I I Illailltallh.:d 111I~ llllu I.lhl.'l PD.\ 
trealment nbstinence through follo\\-up ,'\Ic(,(,~s rates [It po l-tapcl 
were hIgh for both Jlpl1l70lam-only (RWlt) and lombined lherapy 
groll/, if-,i). At ~I.\ 1ll\)lltlJ l'ollov.-up, \llIk ()_I il of the 'ull1l illeJ 
group continued 10 remain inlervention-free, 60% of their drug-only 
counterparts had resumed medication. Those wit rclapscu cit~d 
leaSOI1~ luI' reinstatillg dl ug therapy. Asse. Sll enls al 24-48 nWllth 
post-taper showed that discontinualian . t1ccess rnte had fallen to 
30% and 69.2% for the alprazolam and alprazaJam+CBT groups. A 
sur 1\,,11 analysis indi 'aleL! that discolllinualJoll ItttL:S L: ore taper, 
post-lapel'. and nt 2448-l11onth follow-up wer significanlly 
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d rfelelH I [ween the l\\ll ~I()lli. \LL:: r eSli .tnli,tic:::;lO.S39. df=l. 
p<U. lU5) 
Rept:tltcd Measure. betwrcll buseline, 
3-m0J1lh pUS! laper. ilnd 2· h\ -1-Vl'(ll 1t1llo\\-lIp score. 11 clinician-
rated and df-It:p n ll1t'a~ lilt.', III lilt llllllblllCd group wt'le 
compared 1I ing repealed mea: 1I l', :\. () /\~. O/llnihu tcsts lllal 
ri Ill: l Ii.lik I I It: I t: I II l Ilo' t' I arc graJ11 I all 
I, pll IIIL II hl'lIl't. 
~ 
I Ihal Ie l n the
-
\ II. Il I Hie I" III t I I l:d til J e a1 d I II t: d . I~nj II a II ( , 
rlPm 1\. III I t==J,~ I. 11'= J 2, r 
I III t It=~.IJ( == J I. p< lJ It 
I l=: I __11\ 11 .1' l II II=: L I' 
k,lI II . 01 lhe \ I till 111 L'llh I 1)1. ~lll" 1 hia \\ lil'll 
indicate,II'nil'icance le\'els flOm ba"cll1lc to 3-llIolllh (1=4.43 dl:::;12. 
p<O.OOSI 'Ind ba~clille 1 IOIlg.-IL:11ll 1011 \\-lIP (1=-1.: df=12.I 
p<O,(, I 
Similar findings bctwen baseline and 3-monlll and baseline to 
2 10 4 year follow-up were evinced 011 the other evaluative tests 
n ',·i, (01" 
~i IniJic' 111 over the 11Ica~UIl:J1l~lt PCllOU ([:::2.73. 1'=12, p<O.u5) and 
(t:::2.90 df= ]. p<O.05) respectively as did the means from the Beck 
Depression lnv ntory (l=2.J5, df=12) and (t=2.77 df=1]) 
1e~pe Ii d). fht.- r I ,ll'l SCIl~ilj \ il) III LIlI )Iy Job was dk 1I \ t: 111 
detecting changes in palient funclioning as was seen by the 
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Igrll I ant dt rease In . cores from baseline to .1 I III h~ (t==3.46, 
d == 1 l<l) UJ) alld from baseline to 24· ..j; III 1111 11=3.16, tlr:::: II. 
p<O.t 1 J. ~(lrCS )n the Agoraphobic Cogniliuns ()UL'. tionnain: 
refle lI:J a :-.imilar detrea~e (t::::2.55. 11= 12. P O.U.5 lind (t::::3.80. 
UJ= II p<.O.OO.), f\' cans on the Lmnliollal Conlrnl ()uc'lionnairc \I,Cle 
<11 0 ], nif,c Ilt from baseline to bllll1 3-11l0nlh '1= _.79, uf=12, 
P (I anJ 24-'-1, -l1lc)Jlth follov.-uj> (1= .~/, d = •. p<lJ.ll:). 
\ III \\ hn 
I llt.'d I,ll It: 11'l'1 apeulil,. U LJ 11 I; I • \ 1t 11 anil \\ Il h III 
I . I '( Jl J l''' e III s da l.1 II 
I d at II \ I I 
I \ I I I .. 
\',1.:11.: 1);11 • II Idlel tlJJII Illl lilll1' ~ 1I11lllpall~ 
remillllllg dlug a stincnt ilnu paniL'-IIl't..:. 
rile ft:. ull~ repiJlted heJl' sill \\' that the high sUl'Ct;ssl'ul 
dislI..H) illuali. n I ale. cell ill tJ l nil inctl gil l I Cll: PCI i. tel t 
over two to four years. erllly 70'k of those participants did not need 
to retUJ n to medication and other treatment interventions. 
.. • II , ,:'" \, ' , 't' ( , , 
tell11 foil \\ -up I: nee s 'util) all i lutuble to the CJ3T. hO\\L:ver, is 
speciolls, gl 'en that n CST-only ~rollp was a. se~~ed at the sam 
evaluation pints. tudies examining the long-term effectiveness of 
CllT-lJllly, i ~I bit, have duciJ, k. "leady the bell rits of thi. 
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treatmenl 1ll11JaJil \illl apprOXill1.lll'l y RO?r or pUlient Il1dll1ulining 
therapi.:llli - ~aill (t. 11). 
Impro erne! I c\ident n elf IqH)rI 'Ind clinician·rated 
me.!. lIle ,!lo\\', 11,11 Ille ucce. llf tile alpl dZ lam pIli: 'I~ r 
participants 10 UI. .lll1tinuc medicuillll "a: not due (0 . II I. 
endu anl" If ") 111[1 1lllS stubborn rdusal 10 rein. tale ll1uIJL.ltion, or 
II I I 1)1 J d r II. II. lZl:JU ;1 t. dlilL .-I1Ulllh. alJ _ ..., ­
munth po, Haper) hUI score sllo\\o'd a general decren. e suggesting 
lOIHll1UeU impi Hlnelll from b:lscllllC tl J U. t tar LI \ II I 
IlL III rill r.l1htIL)J};t1 ( 111(1 
Que,lionnaire incrcZl, ed over the course of the study which wa. 
reflective of patients' conception that emotions were more within 
11 " p 
'l''' 1(1 itl,,,·,· 'II , I II ' , 
Ihl repurted Ie.. fLar, and theil U\ oiuullLe of siwatiolL h:J.d 
decrea. cd significantly, Th's A+CBT protocol facilitated Zllpra70lam 
discontinuation an was responsible for clinical changes reflected in 
11' g1l end-stute I II I. iUlling at lung-iLl III rulh.l \\ -lip. 
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• (\ CIa] l:lllli( II 11 ll'~ he.: empluyed in Illterpreting tl1\::c 
r UIIS, however. I- I 011 although Ihe paniupant sample "as 
r lresentative or li.1r~l'r. 'ttldles of PDA 011 man I features. 
~
~el1eralizatioll or the ·iIllJill..:
L 
should be oualllcd due to tile -Ill'll I 
~al1lpk ize. With 23 r:.lt1t:Jlt.. tile power or I U ~tatistic, is Je,s tl'llI 
I 1111:11. Replicatlol1 J-. ncec ~lIY. Also, our Ie. lJh~ suogc.1 thai 
c.: I11hllP'd trcatllll'llt I lllllllVl' ()\'C'I IIlL Oil!. t Jill. but \\ltl1 lUI ;1 
1; ric mell L 
< l ,r the Lila I ,:,t: I I lellt lUll I 11 
I I r I' i\ J! I I l ,IU.d (lJI)
 
eli 'C til
 Ih?SL data : I Illlriguill,L ; I L 
,Ieflll lUll Id 1,111 J1 'J 
11)I11JI 11 .1111111.1 L :::11111 
_I,lltL III ll1allll,lIfi L L.III, Illr\Hlgh lillie Illl11 lUll\!\ II ",1 I..­
mental health profcssj >Ilals an addilional tlcilll11Cnt Optillll. 
( 1111 int:d thelap)' Ila, bLLlI ~howll 10 b I CIl 'I'j 'ial al Ihlt:c-lllonth 
J( II \ -lip (5. 21) . ix-m 'nth !ollo\\'-up C~( .111 I at Oil\.' 'l '11 
e\'aluatjon (] 8). Our results provide the long-h~lm (2- to 4-year) 
data necessary I 11, ur" pra titiollers that implementing this 
j)' IULular method j inte!!/alilll' ern and urug lapel' \ ill lIl" 
I, ling effects, 
Future dire tions could focus on elucidating the In ~chani In of 
action by which integrated therapy has its effects. Other studies 
L d daIs J'le'tly compare err laliL~ of ,CD' 'lone. C IllbillCd hcrapy 
appears to walTan t fUI ther research, 
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ApPl...'lId i 
.STRUCTURED INTERVIEW FOR SHEERAN PANIC AND 
ANTICIPATORY ANXIETY SCALE (Revised tor study) 
subJect Name :D 
In erviewer :at.e 
~cw I wa~:d like to ask y~u atcu~ ar.y pan~~ attacks you may have 
fteXFEr~enced during the ~a8 week. 8) ~par._c attack mea~• 
6pec~fical~y an episcae or spel_ c~r:ng wh~ch you suc=er.:y :elt 
frlghcened or extreme_y ~r.cem:c=~a= e and ~ad at eas~ fc'r of the 
symptoms cn the list 1 w :1 ~~~e you _0 a moment. By ftauddenlyft I 
me n that. ~he symptoms reached the:= maxim~ intensity W~thln 1£ 
minutes from when you f~r8t notic~ they wer there or were get~~~g 
~orse. :t 18 important ~~at you are clear about ow: am def~r. ~g ~ 
~ar.ic a ack. kre ye c:ear ~ou~ trat7 Lo ycu have any ~es~icrs? 
ter: An. r Any que t~on. betcre proc.ed~9) 
Now p ease read carefully through the symptoms on this list, noting 
any you experienced dur1ng the past week that came on suddenly along 
with a feeling of fear or extreme discomfort. Take your time, and 
let me know when you are finished. 
(Ra~.r: Sand pa~ien~ Syapto. List and wait for .iqnal). 
A. PANl:C ~CJtS: 
O.K., now, during the cast week, how many episodes in ~ll have you 
had when vou suddenly felt frigh ened c extremel uncomfortable 
ana exper encea a~ ~ ast tour ~L ~~e sJ~ toms on t.8 _ at l~ 
will ask you later about episodes when you had fewer than 4 
symptoms. ) 
(llatert Verify that all of the episode. reported. in'Yolved at 
le•• t four .~c.. OD the list and r ••ched a peak wi~ 10 
TPN .~utes. Record Muaber!Week in blank at left.) 
1. SI~IOHAL: 
Now of those (in••rt nuab.r) attacks, how many occurred when 
you were in or JU8~ about to go ~ntc a place or situation that, 
~~ your experienc 12 ikel, t= ~~_~g on an a t ck? 
Huaoer/W 
SPD aBsocia~ed with hose situations) last? (Dur.t~oD-.inut.) 
---
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On d scale of 1 to 10, with 1 being the least and 10 being the 
most anxio B o~ uncomfo~tab e you can i, agine, how bad were 
mOBt of thoBe attacks? (Intensity -Score "OR if subject had 
PI _ DO attac)u) 
"PN _ 
• PD 
UPI _ 
B. 
TLN 
2. UNEIPECT1!:D: 
So then of the (total nuaber fro. A) panLc attacks you 
experienced during the past week, (nu.ber fro. A.l) occurred 
when you were in or about to go into a p:ace or situation tha / 
in your experience, is like y to bring or. n attack, and a_I 
the others occJrred when you were not i~ cr about to go into 
suc a place or S~ uati n? Is that correct? 
(Ratert If no, clarify and revise answera to A.l as needed. If 
ye s / proce d) . 
7hat would be a t~tal at (calculat. nu.ber) unexpected panic 
attacks during ~he past week; is that r_~.t~ 
(Rater: If no, revise previous answ.r••• n.eded. If y •• , 
record Nuaber/Week). 
~ow long did most of these unexpected panLc attacks last? 
(Duration-.inutes) 
How bad were most of them cn the to_ scal , 1 being the 
east and C beLr.~ the most uncomtortab: you can imagi e? 
(Int.nsity - Scor RO" if patient had no attacks) 
LIMITED SYMPTOM ATIACXS: 
Now, daring the past week d'd you ever suddenly experience only 1, 
2 or 3 of the symptoms on the list, without naving a ful pan c 
attack? Remember, by "suddenly" I mean that the symptom8 reached 
their maximum intens'ty within 10 minute. from when you first 
noticed they were there or were getting war e. 
(Rater: If y•• , have patient d••cribe worst attack an4qo oy.r 
to .ak. u- \. - :- o.c~ t ~, !"8}?'t 
war., it ..y qualify as a panic attack, in .hich ca•• the an...r. 
in S.dion A ..y n.ed to b. r .... i.ad.) 
In a 1, d ring the past week, how many times did you experience
 
episodes or spells of this limited kind? Don't include the full
 
panic attacks we already discussed. (Nuab.r/...k)
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1. SITUATIONAL: 
Si.. 
Now of those (in.art ouab.r) limited attacks, how many occurred 
when you ~ere in or jvst about to go into a Flace or situation 
that, _n your experience, is likely to bring en an attack? 
(Huab.r! .ek) 
SLD _ 
How long cld most 
those situations) 
of those episodes (the ones 
last? (Duration-~ut•• ) 
assoc~ated with 
SLI _ 
How bad ere most of them on ehe 1 to 10 scale, 1 
least ard 0 being the most ~.comfortable you can 
(InteD.~ty - Score "0" if patient had DO attack.) 
ceing the 
imagine. 
2. tJ'H'Exp !:cnm : 
So then the (total nuab.r fro. 8) limited at~ac~B you 
exper_en e curing he past week, (nuab r fro. B.l) ace rred 
when yo~ ere in or about tc _0 into a pI ce or B~t~a~icn that, 
:n yeur xperie~ce, l8 ~~e / to bring on an attack, and All 
the 0 r.~rE occurred when you were ~ in or abc t ~c go 1 to 
such _ ce or eituatl.cn~ Is t ..at correct? 
(Rater: 
ye., pro 
t no, 
ed.) 
larify ~d revi •• an.",er. to 8.1 •• need-.d. If 
That we 
attacks 
_ 
~. 
be a to a. of (calculate nuaber) ~r. 
ring the past wee~; is that right? 
xpect d limited 
ULN _ 
(Rater; If no, revi.e previous 
record Huaber!Week). 
an.wer••• needed. If ye., 
U'LD 
How long did most of 
(OUr tion-ainut.l) 
these unexpected limited attack. la.t? 
ULI 
How bad were most ot them on the 1 to 10 scale, 1 
least and 10 being the moet uncomfortable you can 
(Intenlit, - Score ·0· if lubject had no attack.) 
being the 
imagine. 
C. ANTICIPATORY ANXIETY 
AAT _ 
Now I would like to get an estimate of how much you have b n 
worrying about having a panic attack. Dyring th. p~.t we.k. 
approximately what percent of the tLme when you were awake and 
were not haVing a panic attack did you worry about having a panic 
attack or about going into a situation that, in your experience, 
is likely to bring on an attack? (\ t~) 
3 
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How many separate times during the past week did you have periods 
of worry about having a panic attack or about going into a 
situation that might cause a panic attack? (Nuaber/week) 
On the average, how anxious or nervous were you during those 
times? Rate your anxiety or nervousness on a scale of 1 to la, 
with 1 being the least and 10 being the most anxious or nervous 
you can imagine? (Inten.ity - Score "0" if .ubject bad no 
AAI attack_) 
4
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Appendix B 
Because of the copyright restrictions and pnce. a copy of the Anxiety 
Di orders Inventory Schedule-Fear could not be obtained. 
---
L< ng-ll'r1l1 El kcl iveness :n 
11 1 
~~arre : [a e:
aegree
dl.scanI: ~ or- anx..l e":'. '-'-' 
laces or 
t: cf 
re wi't..h a us-....ec ~ cr -:; _ Lrt: alene.
'" 
"'ollo..·i.n:; &--, .= 
y 
~ ::: 
-
SUpenrarkets 
ClassrDCXlE 
Museums 
Elevators 
P""'arkl.rg garaop' 
fuar: places 
E:_ i ha,.: ru. 
c 
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~ spaces: 
(A)	 D.Itside (e.g. flelds, ide 
streets I <::o.L"'t'J''a.''1is, 
(B)	 Inside (e.g. larg roams, 
ld::iJies) 
Ridin:J In: 
(A)	 aJses 
Bl	 Trains
 
SU1::M'ays
 
Airplanes 
.aJ'...J..n:j on· E: stree­
--.y:Ln:;j at hare alone .. 
"/ .­
Be:i.nj far away fran hare 
other (specify) 
(1) 
(2) 
(3) 
(4) 
a high level of anxiety accompanied by 
strorq- bcrly reactions (heart palpitations, sweat~, TIU.lSC e 
tre:m:Jrs, dizz iness I n.a.usea) with 
th t.ernpJrary loss of the abil i ty to pIan I t.h.ink, or reason 
the intense desire to escape or flee the situation. (Note, 
.:- c.....d f E:re1i '­ - ron, 1ugh anxie'Cy or 1ear al fIE:.) 
arrl 
this 
Please irriicate the total nt.rr!1ber of panic 
u ~ '-ctC1'..S YOw rli:l e no. 111 the. lase 7 days. _ 
---
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Appendix D 
ANXIETY SENSITIVITY INDEX 
Name:
 
Age: Date: Sex: M F
 
Listed bel !,oJ are a number of statements describing a set of beliefs.
 
Please read each statement carEfully and, on the 0-5 scale given, "ndicate
 
how much you chink each statemenc is typ~ca of you.
 
-----0-----------1-----------2-----------3-----------4-----------5----­
trongly Moderately Slightly Slightly Moderately Stcongly 
Disagree Disagree Cisagree A; ee Agree AgrEe 
l.	 I ~B l.mportant to me not to appear nervous. 
2.	 When I cannot keep my mind on a task, I worry that I might be 
going crazy. 
3.	 It scares me when I feel 'shaky' (trembling) . 
4.	 It scares me when I feel faint. 
S.	 It is important to me to stay in control of my emotions. 
6.	 It scares me when my heart beats rapidly. 
7.	 It embarrasses me when my stomach growls. 
8.	 It scares me when I am nauseous. 
9.	 When I notice that my heart is beating rapidly, I worry that I 
might have a heart attack. 
10. It Bcares me when I become short of breath. 
11. When my stomach is upset, I worry that I might be seriously ill. 
12. I scares me when I am unable to keep my mind on a task. 
13. Other people otice w en I feel shaky. 
4.	 Unusual body sensa ~ore Bcare me. 
16. It scares me when I am nervo 8. 
------------
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Appcndi E 
AGORAH1OBIC o::GNITIONS CUESTIONNAIRF 
Narre: Date:
Bela,..' ­ scxre thooghts or ideas that :ray pass th.rcu~h people I s 
they a ;enrous or frightened. Plecl.se rate ha,y oft;:.J1 @d1 though 
to you you. are nervous. Co l:::y ....~ .iting t.1j~ a rupriate numr:. ~-
from ' .. "ollOw'1..Il;l scale in the space i1eXt to the ":aught. 
cx:x;urs.
 
aught rarely occurs .
 
•00000t occurs during half :: the t.iIDe.s I am r.€l:VOUS. 
" u.sua..:.:..y o:x::urs.
 
~ 01'" ys e:x:.-.....-.Lrs w en I - ne.r,'ous .
 
to thra,...·
 
I· am going to pass out.
 
I must have a brain turror.
 
:r will have a heart attack.
 
I will choke to death.
 
I am goirg to act fCX)lish.
 
I am going blind.
 
I will not be Ie to control myself.
 
I will hurt someone.
 
I am goin;J to have a stroke.
 
I
 am goirg to go crazy. 
I dIn g(;.mgt.o scream.
 
I
 am going to babble or talk funny.
 
I will be paralyzed by fear.
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Plcndi.' F 
IMJI'IONAL mITRaL CUESTIONNAIRE 
Name: 
Aqe:	 cete: _ 5<::::.' I,. F 
Lis-7:Ed bela.. are ::: ..umber of stat.e~P2!.t:S e.-.c:eribing a 5e': cf t __ :.efs. 
F~""~ :.:-e.ac e3cr. _L2':E.rrent care , :1 a..:-D, jn th o-~ 'e ,~ :-=:-, irdica 
h::w ;-~Q '1°- th:r_' rq h stat.e!oc>! __ 5~C2.l of vou. 
.J 2 J t, 5-­
SL-orqly YJCd~': ' 
-1" Slightl::' S::'ightly Mcdera -. Strongly 
~saarE£ DiS3<;Ye-.:' Disagree .~.grE:e Agre~' j'l.oree~-
t!'.e	 decrn:-e +or·... en I rsact -:0 p- rr_I C3n _­
2.	 He"" we....:" ~ CG_ ....ith L s':'t:ua lens dep2rds ~ ....nether .1 
have outs':'de r.e.lp. 
3.	 When I am pJt under stress, I am likely to lose CGntrcl. 
4.	 I can easily turn a diffia.1lt situation into a nana.geable one. 
5. Hy ernotlOl1S seem to have a life of their a.m. 
___6. I can deal successfully with stressful situations. 
__7. Whether I can successfully escape a frighteni.ng situat':'on is 
a , '",'V':" .. -.'" pr of cr.a1Y'e ,-1 ....1" TTY='. 
__8.	 I can tlSllally influe.rce tJ e degree to which as' b.1a .'.-::m is 
p:>tentially threatening to Ire. 
9 . The degree to which I react to prob ems is out of control. 
10.	 The extent to which a dittia.1lt situation resolves iLc.elf has 
nothirq too do with my a ':'ons. 
11.	 There' 5 not.h.J.ng I can do to stop a.ruuety once . t nas started. 
12 . Any	 little can make me uptight. 
13.	 I eel 1 ;1,. _ am the victim cf mv e.rrotions. 
()T1~-lcrm Etf'c.:tl 1:11' 
« t. 
" II 
'.
... 
4 'I-' 'IS nluch ::;allsfac 'or _It of Ll .n:rs as I 
"'I (. to 
'I,joy thil gs rll, v". 
Jl' [2'.T l"Pc.! s<tlisl~\('ti( I thin!.: 
5 01.' ft ,lpalt"c JUri} 11':, 
I fel lilty a CTa d part f h timf_ 
le 1qUIl . guilt' n st of tb - tun 
feel guilty all 0 th line. 
B 
i • 
• It • 1 1arn beifll! [lunistwd. 
7 r' II 
.. 
• U .. , 
n 
r~ ,.. 
" 
11 
12 irr'" 
r peopl han 
. in tel'f'~ tin 
.. 'tr.(" c::'". .. 
O. II', ens 
ed in oth 
.,. , : 
l' 
••• ~' or 
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14 (J I do 't f el I look any worse than I used to. 19 I haven't 10 t much wight. if any, lately. 
I a worried that I am looking old or I have lost rna than ­ pounds. 
unattractiv . I have lost mar than 10 pounds.
If el that th re are permanent changes 
in m ppearanc that mak m oak I ha east m re than 15 pounds. 
unat ractive. 
:J I believe that I look ug1 I am purposely trying to ose weight by 
eat'ng less. Ye • 0 _ 
15 u I can work about as w U before. 
It takes an extra dfort to get starle 
oin somethina. 
at 20 1 am no n or than usual. worried about my health 
I h ve to push mys U' very hard t 
nythmg. 
do I am worried abou t physical probl 
such as ach s and p~ins; or upset 
stoma h; r constipation. 
IDS 
I can" do any w rk at aU. I am very worried about physlCal 
probLms and it's hard 0 hin.k of 
much dse 
18 I can sleet:' as \ ..... 11 as usual. 
I lion t sl e as w -11 a I us d t 
am so ... onied about m. physical 
problems that I annot thnk about 
anyLhing Is 
I wake UP 1-2 hours earlier than sual 
nd Lnd lt hard t g back to 1 
1\ ak 
sed 
up s 'era1 hours ear1i r than I 
a (1 calmol "t ack to ~ t'!tt" 21 I have not noticed ar . n~cent 
in my lntere 't in f'f'.'. 
'hancre 
I am less lnterested i. !'ie,' than I used 
to b 
17 1dC>l't g=>t more tired han usual am much k:ss interested:.n ex O\\'. 
I get til' 'd more easil) than I used o. I ave lost inter st in sex campi tely. 
I get tired from doing almost anything. 
.J I am too 'ired to do anything. 
18 ') yapp tite is 110 wors than usual. 
My appetite is not as good as it used to be. 
My appetite is much worse now. 
J I have no app tite t all anymore. 
_______ '-u ... 
___ Subtotal Page 1 
___ Total Score 
" 
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Figure Le nd and Footnote 
FIGURE 1. Percentage of Patients Achieving and Maintaining Drug 
and Other PDA Treatment Abstinence in Alprazolam-Only and 
Alprazolam Plus Cognitive-Behavioral Therapy Groups at 24 to 
48-Monrh Follow-Up.l 
Footnol~: 
ISignificanl difference between urvival distributic n from before 
tap r to 24-48 months after tap r (Le -Desu statililic= I0.539, df= I, 
p<O.005 ) 
FIGURES 2-8. Changes in Mean Scores on Se) f-Report and Clinician­
Rated Measures at Baseline, 3-Month Follow-Up, and 24-48-Month 
Follow-Up in the Combined Treatm nt Group (Significance 
Dif rences Denoted by *). 
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